Financial writer discusses MGX's gene editing technology, cash runway, and lack of clinical data for potential future ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Learn more about whether Catalyst Pharmaceuticals, Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...

A GROUNDBREAKING genetic treatment with the potential to cure sickle cell disease will be rolled out on the NHS. The one-off ...

In a challenging year for biotech firms, Caribou Biosciences Inc. has seen its stock tumble to a 52-week low, touching down at $1.32. According to InvestingPro data, the stock's RSI indicates oversold ...

The fall in CRSP stock can be attributed to ... It became the first gene-editing treatment that uses the Nobel Prize-winning CRISPR technique, an impressive achievement by CRISPR Therapeutics.

Learn more about whether Legend Biotech Corporation or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Intellia Therapeutics, Inc. shares declined over 5% on Monday morning after Morgan Stanley downgraded the stock to ‘Equal ...

Design Therapeutics' GeneTAC platform is revolutionizing genetic disease treatment with small molecules and promising results ...

DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.

Since that discovery, a flurry of gene-editing focused biopharma companies have launched – including Intellia Therapeutics, CRISPR Therapeutics ... and with stock prices rising for editing ...